Some patients with non-insulin-dependent (Type 2) diabetes mellitus (NIDDM) are positive for antibodies to glutamic acid decarboxylase (anti-GAD), which have been shown to be a useful marker for the diagnosis and prediction of insulin-dependent (Type 1) diabetes mellitus (IDDM). Anti-GAD positive NI
โฆ LIBER โฆ
Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis
โ Scribed by Michael P. Malter; Christoph Helmstaedter; Horst Urbach; Angela Vincent; Christian G. Bien
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 355 KB
- Volume
- 67
- Category
- Article
- ISSN
- 0364-5134
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Antibodies to Glutamic Acid Decarboxylas
โ
Fukui, M.; Nakano, K.; Shigeta, H.; Yoshimori, K.; Fujii, M.; Kitagawa, Y.; Mori
๐
Article
๐
1997
๐
John Wiley and Sons
๐
English
โ 124 KB
๐ 1 views
Elimination of islet cell antibodies and
โ
W. O. Richter; M. G. Donner; P. Schwandt
๐
Article
๐
1997
๐
John Wiley and Sons
๐
English
โ 69 KB
๐ 2 views
Islet cell antibodies and glutamic acid decarboxylase II (GAD II) antibodies have been discussed in the autoimmune pathogenesis of insulin-dependent diabetes mellitus (IDDM). Hence, immunosuppressants, intravenous immunoglobulins, and plasmapheresis have been used in an effort to modulate autoimmune